Figure 3From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus The filtered glucose load (%) vs dose in healthy volunteers (filled circles) and subjects with T2DM (open triangles). Back to article page